Table 6

IgH VDJ gene segments and amino acid sequence of CDR3 region at baseline, at the end of therapy, and at the end of follow-up in 10 nonresponsive MC patients treated with PIRR or with the Peg-IFN-α/RBV standard therapy

TreatmentDH familyJH familyAmino acid sequence
PIRR    
    Patient no. 1    
        Start D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
 D3-22*01 JH4*03 CAKMGSSGWPYFDYW 
 D6-19*01 JH3*02 CAKYLGDSSGYYSDAFDIW 
 D2-2*01 JH4*01 CARAEDIVVVPAAMAFDYW 
        End of therapy D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
        End of follow-up D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
    Patient no. 2    
        Start D6-6*01 JH4*03 CARAVGYHRSSAGYFDYW 
        End of therapy D6-6*01 JH4*C3 CARAVGYHRSSAGYFDYW 
        End of follow-up D6-6*01 JH4*C3 CARAVGYHRSSAGYFDYW 
    Patient no. 3    
        Start D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
        End of therapy D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
        End of follow-up D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
    Patient no. 4    
        Start D2-2*01 JH4*03 CARDWEYCSSTSTSCFFDYW 
        End of therapy — — — 
        End of follow-up — — — 
    Patient no. 5    
        Start D1-1*01 JH5*02 CARDRQLELLDPW 
        End of therapy D1-1*01 JH5*02 CARDRQLELLDPW 
        End of follow-up D1-1*01 JH5*02 CARDRQLELLDPW 
Peg-IFN-α/RBV    
    Patient no. 1    
        Start D3-10*01 JH4*01 CATGLGSYLFDYW 
        End of therapy D3-10*01 JH4*01 CATGLGSYLFDYW 
        End of follow-up D3-10*01 JH4*01 CATGLGSYLFDYW 
    Patient no. 2    
        Start D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
        End of therapy D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
        End of follow-up D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
    Patient no. 3    
        Start D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
        End of therapy D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
        End of follow-up D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
    Patient no. 4    
        Start D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
        End of therapy D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
        End of follow-up D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
    Patient no. 5    
        Start D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 
        End of therapy D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 
        End of follow-up D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 
TreatmentDH familyJH familyAmino acid sequence
PIRR    
    Patient no. 1    
        Start D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
 D3-22*01 JH4*03 CAKMGSSGWPYFDYW 
 D6-19*01 JH3*02 CAKYLGDSSGYYSDAFDIW 
 D2-2*01 JH4*01 CARAEDIVVVPAAMAFDYW 
        End of therapy D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
        End of follow-up D2-15*01 JH6*02 CARGRGKLYYYGLDVW 
    Patient no. 2    
        Start D6-6*01 JH4*03 CARAVGYHRSSAGYFDYW 
        End of therapy D6-6*01 JH4*C3 CARAVGYHRSSAGYFDYW 
        End of follow-up D6-6*01 JH4*C3 CARAVGYHRSSAGYFDYW 
    Patient no. 3    
        Start D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
        End of therapy D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
        End of follow-up D5-5*01 JH2*01 CARDFGGDTAMVYWYFDLW 
    Patient no. 4    
        Start D2-2*01 JH4*03 CARDWEYCSSTSTSCFFDYW 
        End of therapy — — — 
        End of follow-up — — — 
    Patient no. 5    
        Start D1-1*01 JH5*02 CARDRQLELLDPW 
        End of therapy D1-1*01 JH5*02 CARDRQLELLDPW 
        End of follow-up D1-1*01 JH5*02 CARDRQLELLDPW 
Peg-IFN-α/RBV    
    Patient no. 1    
        Start D3-10*01 JH4*01 CATGLGSYLFDYW 
        End of therapy D3-10*01 JH4*01 CATGLGSYLFDYW 
        End of follow-up D3-10*01 JH4*01 CATGLGSYLFDYW 
    Patient no. 2    
        Start D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
        End of therapy D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
        End of follow-up D3-3*01 JH5*02 CAREVNFGVVGWFDPW 
    Patient no. 3    
        Start D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
        End of therapy D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
        End of follow-up D3-3*01 JH4*03 CAGSGILRFLEWSGAFW 
    Patient no. 4    
        Start D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
        End of therapy D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
        End of follow-up D1-20*01 JH6*03 CAKAGGAFSTWFRNDRDAGFYNYMDVW 
    Patient no. 5    
        Start D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 
        End of therapy D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 
        End of follow-up D2-2*01 JH4*03 CAKAEPPYGGSTSCPDYYW 

— indicates not detected.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal